Qinec Appoints Jim Horsburgh as Chairman - Gilde Healthcare

Qinec Appoints Jim Horsburgh as Chairman

7. Dezember 2015

Industry veteran joins digital health company

LONDON – Qinec, a digital health company focused on cloud based Personalised Healthcare Management, today announced that healthcare IT veteran Jim Horsburgh has joined Qinec’s board as a non executive member and been appointed as independent chairman.

Robbie Hughes, CEO at Qinec said:

“Qinec’s Personalised Healthcare Management platform has been adopted by many of the UK’s largest commercial healthcare providers. Jim’s expertise as a chairman of numerous digital health companies will be invaluable in guiding Qinec through the next stage of growth.”

Jim previously served as Chairman of healthcare IT company System C, leading the company through its successful IPO and acquisition by McKesson. He also served as SVP Worldwide Marketing at Visio through its IPO and acquisition by Microsoft, and in business development and marketing roles at CentralPoint Software, Lotus and Olivetti. Jim currently serves as chairman for Insource, a data warehousing automation solution specialising in healthcare, and chairman for Shearwater, a developer of mobile solutions for healthcare. He’s previously served as chairman for ScriptSwitch Ltd. and Triaster Ltd.

Jim Horsburgh said:

“Qinec has had a huge impact on healthcare, challenging the legacy, siloed mentality of healthcare IT by focusing its approach on the orchestration of the patient journey. Qinec has established itself as a trusted agent of change within the industry; its proposition is compelling for patients, providers and payers alike.”

About Qinec

Qinec is a UK-based digital health company providing Personalized Healthcare Management (PHM) solutions. The company’s cloud-based SaaS platform uses real time data to orchestrate the patient journey to achieve optimal outcomes for patients, providers and payers at lower cost. Managing millions of patients a year across Europe, Qinec tailors processes and optimizes clinical and administrative workflows across every specialty of outpatient care. For more information about Qinec please visit www.qinec.com.

Press Contact:

Michele Moore
PR Manager
+44 07507 246 961
Michele.Moore@qinec.com

Gilde Healthcare company Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield

Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. ReActiv8...
28. April 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of...
22. April 2025

Gilde Healthcare company SynOx Therapeutics announces Board Chair transition to align with advancing Regulatory and Commercialization Strategy

SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the execution of a planned and orderly transition of its board chair position. Philip Astley-Sparke...
1. April 2025